More about osteonecrosis

J Am Dent Assoc. 2011 Apr;142(4):371-2; author reply 372-4. doi: 10.14219/jada.archive.2011.0183.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents / adverse effects
  • Bone Density Conservation Agents / adverse effects*
  • Denosumab
  • Dental Care
  • Diphosphonates / adverse effects*
  • Drug Interactions
  • Humans
  • Imidazoles / adverse effects*
  • Jaw Diseases / chemically induced*
  • Oral Hygiene
  • Osteonecrosis / chemically induced*
  • RANK Ligand / adverse effects
  • Risk Factors
  • Zoledronic Acid

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Bone Density Conservation Agents
  • Diphosphonates
  • Imidazoles
  • RANK Ligand
  • Denosumab
  • Zoledronic Acid